Patent Foramen Ovale and Stroke: Closure by Further Randomized Trial Is Required!

Stroke

Volumn 35, Issue 3, 2004, Pages 806-

  Donnan, Geoffrey A ^a   Davis, Stephen M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Foramen ovale, patent; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEVICE; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT LEFT SHUNT; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CEREBROVASCULAR ACCIDENT; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS;

EID: 1442323794     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000117965.15684.D3     Document Type: Review

References (3)

1. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-1746.
2. Jones EF, Calafiore P, Donnan GA, Tonkin MA. Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly. Am J Cardiol. 1994;74:596-599.
3. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, for the PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale. Circulation. 2002;105:2625-2631.